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Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S167overall survival (OS) was 54% (95% CI, 41e66%) for the entire
cohort with an OS for NNGF of 73% (95% CI, 55 e 85%) and for
NGF OS was 30% (95% CI, 14e47%) (p<0.01). A second GF
occurred in 18 (67%) NGF and in 9 (26%) NNGF patients. Viral
studies showed there was more frequent HHV6 reactivation,
with 48% of the NGF group versus 8.8% of the NNGF group (p<
0.01) having reactivation. EBV and CMV reactivate was not
different. The most common cause of death after second HCT
was persisting GF leading to infection or infection despite
engraftment. Outcomes of second HCT for NGF and NNGF are
different with very poor outcomes for the NGF group, neces-
sitating new approaches to improve overall survival.206
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B-cell immune dysfunction substantially contributes to the
risk of severe infections after allogeneic hematopoietic stem
cell transplantation (alloHSCT). B-cell numbers normalize
within one year after transplantation, howevermanypatients
display a slow recovery of CD27+ memory B cells and week
vaccination responses. Little is known about functional B-cell
deﬁcits associated with memory deﬁciency post-transplant.
In our study we quantitatively and phenotypically
analyzed B- and T-cell subsets in peripheral blood by ﬂow
cytometry at days 180 and 360 after alloHSCT in acute
leukemic patients (n¼36). In addition, apoptosis of B-cell
subsets was investigated after stimulation with CpG and
CD40L. To address the B-cell milieu cytokines and chemo-
kines were measured with Luminex technology.
Half of patients at day 180 and all patients at day 360 dis-
played fully restored absolute B-cell numbers, although
CD27+ memory B-cell subsets remained diminished (cells/
mlSEM: healthy control (HC) 264, alloHSCT 41;
p0.001). All B-cell subsets were characterized by an acti-
vated/pro-apoptotic phenotype with an increased CD86 and
Fas but reduced Baff-R expression at day 180. Accordingly, an
inﬂammatory milieu was present with increased serum
levels of TNFa, IFNa2, G-CSF, IP-10, MCP-1, MIP-1b and
Eotaxin in patients compared to HC. While CD86 normalized
at day 360 on most B-cell subsets, all subsets retained a
strong pro-apoptotic phenotype with increased Fas and
reduced Baff-R expression. Interestingly, stimulation of pe-
ripheral blood mononuclear cells with CpG and CD40L
resulted in signiﬁcantly increased percentages of apoptotic
cells for the patients compared to HC (% of B cellsSEM: HC
112, alloHSCT 285 day180, 606 day 360; p0.001).
Regarding the lack of CD27+ memory B-cell recovery, we
assumed a defective germinal center (GC) reaction. Supporting
this suggestion we found (A) a reduced CXCR5 expression on
naïve B cells, important for the entry into B-cell follicles
(MFISEM:HC 5899975, alloHSCT 3494554; p0.01), (B) a
low HLA-DR expression on naïve B cells, essential for antigen
presentation (HC204404742, alloHSCT91502386;p0.01),
(C) a normalnumberof CD27-IgD- doublenegative (DN) B cells,suggested to prematurely leave the GC reaction, (D) a
remaining CD4+ T-cell deﬁciency (cells/mlSEM: HC 97277,
alloHSCT 30345; p0.001) and (E) a reduced percentage of
circulating CXCR5+ follicular T helper cells, importantly
involved in GC reactions (%SEM: HC 62, alloHSCT 21).
We conclude that a sustained inﬂammatory milieu and
possibly damage within lymphoid organs might contribute
to a prolonged pro-apoptotic state of B-cell subsets and de-
fects in the GC reaction long-term after allo-HSCT. Despite
normal total B-cell numbers signiﬁcant functional deﬁcits
exist more than one year after transplant, so that adoptive
transfer of memory CD27+ B cells should be pursued.207
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Introduction: Favorable IR after allo-SCT has been reported
after reduced intensity conditioning (RIC); however, T-cell
depletion and cord blood (CB) SCT have been associated with
delay in IR. The goal of this study is to compare the rates of IR
using three different transplant strategies employed at
UMass Memorial Medical Center.
Patients & Methods: We retrospectively analyzed data of all
patients who underwent allo-SCT at our institution since April
2009 using either RIC with thiotepa/ﬂudarabine/melphalan
followed by post-transplant cylophosphamide (TFM/Cy arm),
RIC with Fludarabine/Busulfanx2/antithymocyte globulin
(FluBu2/ATG arm) or CB transplant with TFM/ATG regimen. IR
was assessed by rates of recovery of lymphocyte subsets
(CD3, CD4, CD19, CD25+127- and NK-cells) and serum
immunoglobulins (Ig’s)atD30,D100and1yearpost transplant.
Results: 102 patients were identiﬁed from the database. 38
patients (37.2%) were included in the TFM/Cy arm, 38 pa-
tients (37.2%) in the FluBu2/ATG arm and 26 patients (25.5%)
in the CB arm. Median age of all patients was 62.2 years
(range 18.4 e 83.5) and 52.4, 67.5, and 63 years in the TFM/
Cy, FluBu2/ATG and CB arms, respectively. Median lympho-
cyte subset counts and Ig levels at different post transplant
points are detailed in Table 1. CD3 and CD4 recovery was
signiﬁcantly inferior in the CB arm at D30 and D100. There
was a trend towards delayed IR of regulatory T-cells
(CD25+127-) in the CB arm at all points. CD19 and NK-cell
recovery was superior in the CB arm at all points, but NK-
cell recovery did not reach statistical signiﬁcance at 1 year.
Recovery of serum Ig’s was noted to be faster in the
FluBu2/ATG arm early on post transplant. At 1-year post
allo-SCT, Ig values were comparable in all arms.
Table 1
Cells/mm3 All Patients TFM/Cy FluBu2/ATG CB P value
CD3- D30 284 376 277 16.5 <0.0001
D100 518 598.5 1159 125 <0.0001
1 year 669 744.5 690 244 0.13
CD4- D30 100 111 129.5 4 <0.0001
D100 175 189 276 53 <0.0001
1 year 251 293 269 141 0.08
CD19- D30 2 1 8 2 <0.0001
D100 41.5 24 73.5 273.5 0.03
1 year 184.5 204 96 925 0.01
T-reg D30 14 16 10.5 2 0.06
D100 18.5 20 29.1 5.5 0.13
1 year 22 21.5 38 12.5 0.14
NK-cells- D30 136 29 205 264 <0.0001
D100 150 110 201 269 0.001
1 year 143 132.5 148 166 0.53
IgA- D30 59 46 147 54 <0.0001
D100 60.5 26 131 33.5 <0.0001
1 year 58 51 45 77.5 0.13
IgG- D30 593 534 763 548 0.01
D100 612 494 656 592 0.45
1 year 760 784 742 878 0.46
IgM- D30 29 23.1 58.6 28.1 0.01
D100 30.2 17.0 80.2 58.9 <0.0001
1 year 52.2 42.2 53.8 81.1 0.25
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S168Conclusion: Our results show that CB allo-SCT with TFM/
ATG conditioning was associated with faster recovery of NK-
cells and CD19 cell; however with delayed recovery of T-
lymphocyte subsets. Recovery of T-lymphocyte subsets was
almost comparable in both arms receiving allo-SCT with RIC
regimen regardless of the use of post-tx Cy vs ATG. FluBu2/
ATG regimen was associated with faster recovery of serum
Ig’s in the early post-transplant period.
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Umbilical cord blood transplantation (UCBT) is characterized
by delayed immune reconstitution even with the use of
double unit UCBT (dUCBT). Previously we reported that
reconstitution of thymopoiesis, as determined by assessment
of T-cell receptor excision circles (TRECs), plays a critical role
in the clearance of CMV viremia and is associated with
improved overall survival in dUCBT recipients. We also
determined that recovery of speciﬁc T-cell subsets after
dUCBTcorrelates with serum levels of Interleukin 7 (IL-7) and
Stem Cell Factor (SCF). Here we investigated whether thymic
reconstitution depends on IL-7 and SCF and examined the
prognostic role of TRECs, IL-7 and SCF levels in clinical out-
comes after dUCBT. Fifty-two patients with hematologic ma-
lignancies received dUCBT following either reduced-intensity
(ﬂudarabine, melphalan and antithymocyte globulin) or
myeloablative conditioning (ﬂudarabine, cyclophosphamide
and TBI). GvHD prophylaxis was tacrolimus in combination
with sirolimus ormycophenolatemofetil. The incidence rates
of grade II-IV acute GvHD and chronic GvHD were 15.4% and
29% respectively. The 5-year cumulative incidence of relapse,non-relapse mortality (NRM), progression-free survival (PFS)
and overall survival (OS) were 43%, 31%, 26%, and 41%
respectively. During the ﬁrst 3 months after dUCBT, TRECs
remained undetectable or extremely low but, at 6 months,
69.7% of patients had detectable levels. At one year, TRECs
were detectable in 86.6% of patients with a median value of
2404 copies/ug DNA. Serum levels of IL-7 increased 3-fold
from baseline by 1 month after dUCBT, remained elevated
through the ﬁrst 3 months, and gradually declined to pre-
transplant levels by1 year. SCF levels peakedat 2months after
dUCBT and gradually declined thereafter. We observed a sta-
tistically signiﬁcant inverse correlationbetweenTRECsand IL-
7 (p¼0.036) or SCF (p<0.02) serum levels at various time
points after dUCBT, suggesting that uptake of these two cy-
tokines by thymocytes may lead to their differentiation into
TREC-containing Recent Thymic Emigrants (RTE). In multi-
variable analysis, higherTREC levels independentlycorrelated
with improved OS (p¼0.02) and lower NRM (p¼0.008).
Conversely, higher levels of SCFand IL-7 correlatedwith lower
OS (p¼0.005andp<0.0001). Furthermore, SCF level predicted
NRM (p¼0.003), whereas serum IL-7 level independently
predicted cGvHD (p¼0.03). Taken together, our ﬁndings sug-
gest that high IL-7 and SCF serum levels are associated with
delayed thymic reconstitution and may predict adverse out-
comes after dUCBT, including cGvHD, NRM and OS.
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